Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 13/20 | 0.80 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CCR1 | P32246 | 5/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4164112 | 0.94 | NR3C1 (0.82) | NR3C1USP30PGRCYP3A4CYP2C9 | |
| SCHEMBL14403954 | 0.94 | NR3C1 (0.82) | NR3C1USP30PGRCYP3A4CYP2C9 | |
| SCHEMBL4168041 | 0.89 | NR3C1 (1.00) | NR3C1PGRCYP3A4CYP2C9 | |
| SCHEMBL4168046 | 0.87 | NR3C1 (0.72) | NR3C1USP30PGRCYP3A4CYP2C9 | |
| SCHEMBL4164098 | 0.84 | NR3C1 (0.91) | NR3C1PGRCYP3A4CYP2C9 | |
| SCHEMBL4158339 | 0.82 | NR3C1 (0.76) | NR3C1PGRCYP3A4CYP2C9CCR1 | |
| SCHEMBL4170199 | 0.81 | NR3C1 (0.73) | NR3C1PGRCYP3A4CYP2C9CCR1 | |
| SCHEMBL4176927 | 0.80 | NR3C1 (0.83) | NR3C1PGRCYP3A4CYP2C9 | |
| SCHEMBL4158915 | 0.80 | NR3C1 (0.71) | NR3C1PGRCYP3A4CYP2C9CCR1 | |
| SCHEMBL4171102 | 0.79 | NR3C1 (0.65) | NR3C1CCR1CYP17A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170898-A1 | Sulphonamide Derivatives as Modulators of the Glucocorticoid Receptor | BENGTSSON MALENA | 2009-07-02 | — | — | US | disclosed |
| US-20090170898-A1 | Sulphonamide Derivatives as Modulators of the Glucocorticoid Receptor | BENGTSSON MALENA | 2009-07-02 | — | — | US | disclosed |
| US-20090170898-A1 | Sulphonamide Derivatives as Modulators of the Glucocorticoid Receptor | BENGTSSON MALENA | 2009-07-02 | — | — | US | disclosed |
| WO-2007114763-A1 | SULPHONAMIDE DERIVATES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR | ASTRAZENECA AB (SE) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170898-A1 | Sulphonamide Derivatives as Modulators of the Glucocorticoid Receptor | NR3C1, NR3C2, NR5A1 | NR3C1 1/4885USP30 3149/4885PGR 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.